Abstract | INTRODUCTION: METHODS AND RESULTS: Here, we show that combined treatment of SRA737, an oral CHK1 inhibitor, and anti- programmed death ligand 1 (PD-L1) leads to an antitumor response in multiple cancer models, including SCLC. We further show that combining low, non-cytotoxic doses of gemcitabine with SRA737 + anti-PD-L1/anti-PD-1 significantly increased antitumorigenic CD8+ cytotoxic T cells, dendritic cells, and M1 macrophage populations in an SCLC model. This regimen also led to a significant decrease in immunosuppressive M2 macrophage and myeloid-derived suppressor cell populations, as well as an increase in the expression of the type I interferon beta 1 gene, IFNβ, and chemokines, CCL5 and CXCL10. CONCLUSIONS: Given that anti-PD-L1/anti-PD-1 drugs have recently been approved as monotherapy and in combination with chemotherapy for the treatment of SCLC, and that the SRA737 + low dose gemcitabine regimen is currently in clinical trials for SCLC and other malignancies, our preclinical data provide a strong rational for combining this regimen with inhibitors of the PD-L1/PD-1 pathway.
|
Authors | Triparna Sen, Carminia M Della Corte, Snezana Milutinovic, Robert J Cardnell, Lixia Diao, Kavya Ramkumar, Carl M Gay, C Allison Stewart, Youhong Fan, Li Shen, Ryan J Hansen, Bryan Strouse, Michael P Hedrick, Christian A Hassig, John V Heymach, Jing Wang, Lauren A Byers |
Journal | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
(J Thorac Oncol)
Vol. 14
Issue 12
Pg. 2152-2163
(12 2019)
ISSN: 1556-1380 [Electronic] United States |
PMID | 31470128
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2019 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved. |
Chemical References |
- Heterocyclic Compounds, 4 or More Rings
- Programmed Cell Death 1 Receptor
- SRA737
- Deoxycytidine
- Gemcitabine
|
Topics |
- Administration, Oral
- Animals
- Combined Modality Therapy
(methods)
- Deoxycytidine
(analogs & derivatives, pharmacology, therapeutic use)
- Female
- Heterocyclic Compounds, 4 or More Rings
(pharmacology, therapeutic use)
- Humans
- Immunotherapy
(methods)
- Lung Neoplasms
(drug therapy, pathology)
- Mice
- Programmed Cell Death 1 Receptor
(antagonists & inhibitors)
- Small Cell Lung Carcinoma
(drug therapy, pathology)
- Tumor Microenvironment
(immunology)
- Xenograft Model Antitumor Assays
- Gemcitabine
|